Loading...
Market
What will IDEAYA's market share in ADC therapies for SCLC be by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Industry reports and market analysis from firms like IMS Health or EvaluatePharma
Story
IDEAYA Biosciences Licenses SHR-4849 from Hengrui Pharma for $75M, Total Payments Around $1B, Targeting SCLC and NET Tumors
Dec 29, 2024, 11:02 AM
IDEAYA Biosciences has entered into an exclusive licensing agreement with Hengrui Pharma for SHR-4849, a novel drug currently in Phase 1 development. This drug is a DLL3 Topo-I-Payload antibody-drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine tumors (NET). The licensing deal is valued at approximately $75 million, with potential total payments reaching around $1 billion. This move reflects a growing trend where biotechnology companies are increasingly sourcing innovation from China, highlighting the shifting dynamics in the pharmaceutical landscape.
View original story
Similar markets
Lower • 25%
Third • 25%
Second • 25%
Leading • 25%
AstraZeneca • 25%
Other • 25%
Roche • 25%
Johnson & Johnson • 25%
No • 50%
Yes • 50%
Less than 20% • 25%
40% to 60% • 25%
More than 60% • 25%
20% to 40% • 25%
Pfizer • 25%
AstraZeneca/Daiichi Sankyo • 25%
Other • 25%
Roche • 25%
10% to 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
More than 15% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Significant Improvement • 25%
No Change • 25%
Moderate Improvement • 25%
Worse Outcomes • 25%
5% to 10% • 25%
More than 20% • 25%
10% to 20% • 25%
Less than 5% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
Less than 20% • 25%
More than 60% • 25%
40% to 60% • 25%
20% to 40% • 25%